Jazz Pharmaceuticals plc announced that it will share six research abstracts—including one oral presentation—at the 2026 American Academy of Neurology (AAN) Annual Meeting, scheduled for April 18–22, 2026, in Chicago.

These presentations highlight the scope of Jazz’s neuroscience work across epilepsy and sleep disorders. The data include new clinical findings on Epidiolex® (cannabidiol) in patients with conditions such as Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), tuberous sclerosis complex (TSC), and other difficult-to-treat epilepsies, as well as research on Xywav® (a mixed oxybate oral solution) in individuals with narcolepsy.

Jessa Alexander, Ph.D., who leads the neuroscience therapeutic area in global medical and scientific affairs at Jazz Pharmaceuticals, noted that the company remains committed to addressing unmet needs in rare neurological conditions. She emphasized that ongoing studies of Epidiolex and Xywav are helping deepen insights into these complex disorders, better reflect patient experiences, and guide research efforts toward improving care where gaps still exist.

Key highlights from the meeting include:

All abstracts from the 2026 AAN Annual Meeting are available online.

Jazz Pharmaceuticals remains dedicated to its mission of developing transformative medicines for individuals with serious illnesses who have limited treatment options. By creating innovative treatments, we aim to help patients lead fuller lives. Our patient-centered approach underpins our Corporate Sustainability and Social Impact (CSSI) strategy.
 
In 2023, we celebrated our 20th anniversary, marking two decades since Jazz Pharmaceuticals was established to address unmet medical needs with groundbreaking medicines. We have fostered a culture that prioritizes people and purpose, which has been integral to our growth and success as an innovative biopharmaceutical company.
 
Over the past year, we focused on enhancing the governance of our CSSI strategy to ensure positive impacts across our key pillars: Patients, People, Community, and Planet. Our Board and executive management set the long-term vision for our CSSI strategy, ensuring it aligns with our mission, culture, and business goals. Key members of our Executive Committee are responsible for executing the strategy within each CSSI pillar, facilitating the integration of CSSI considerations into our daily operations, supporting our growth strategy, and meeting regulatory expectations.
 
We made significant progress across our CSSI pillars, including advancing our mission to provide treatments for patients with limited options. This included expanding access to our medicines and initiating new clinical trials. We also launched an initiative to ensure the diversity of participants in our clinical trials reflects our patient populations.
 
Jazz continues to strive to be the best workplace for our employees. Our approach supports the development of their skills and capabilities in oncology and neuroscience. We take pride in our high employee engagement, with over 75% response rates on our surveys, and active participation in our Employee Resource Teams, fostering a diverse and inclusive work environment.
 
We maintained our commitment to positively impacting communities by focusing our philanthropy and volunteer efforts on causes important to our employees and mission. We supported various initiatives, including partnerships with Stand Up To Cancer and the American Heart Association, through education, funding, and medical donations.
 
We are also making progress in reducing our environmental impact. In 2023, our Athlone, Villa Guardia, and Kent Science Park sites purchased 100% renewable electricity. We are increasing efforts to monitor environmental data across our sites to enhance our sustainability approach.
 
As we advance our CSSI strategy this year, we are preparing for increased sustainability reporting regulations. Throughout 2024, we will focus on creating positive impacts for patients, people, society, and the planet. By providing access to innovative medicines, fostering a talented workforce, giving back to our communities, and reducing our environmental footprint, we aim to further our capabilities as a responsible, innovative biopharmaceutical company.
 
Best regards,
 
Bruce C. Cozadd 
Chairman of the Board and Chief Executive Officer